SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST

Their core work

Sheffield Teaching Hospitals is one of the UK's largest NHS hospital trusts, providing acute and community healthcare services across Sheffield. In the EU research landscape, they contribute real-world clinical data, patient cohorts, and frontline medical expertise to multi-centre studies — particularly in diabetes management, drug safety imaging, and digital health assessment. Their role is typically that of a clinical validation site, offering access to diverse patient populations and established care pathways that allow research innovations to be tested in genuine healthcare settings.

What they specialise in

How they've shifted over time

Sheffield Teaching Hospitals entered H2020 through cardiovascular simulation projects (VPH-CaSE, EurValve) in 2015-2016, focusing on computational modelling for personalised medical devices and heart valve disease. From 2017 onward, their involvement shifted decisively toward clinical data provision and digital health validation — contributing patient cohorts for imaging biomarker studies, diabetes data harmonization, and digital mobility outcomes. This trajectory shows a clear move from being a partner in simulation-heavy research toward becoming a trusted source of real-world clinical evidence for digital and data-driven health innovations.

STH is positioning itself as a clinical validation hub for digital health tools and data-driven diagnostics, making them a strong partner for projects needing real-world NHS patient data.

How they like to work

STH never coordinates projects — they participate as partners or, more frequently, as third-party contributors providing clinical sites, patient data, and medical expertise. With 5 of 7 projects as a third party, they operate as a specialist clinical resource that larger consortia bring in for validation and data access. Their 122 unique partners across 17 countries indicate they are well-networked but selective, joining large established consortia rather than leading or building their own.

With 122 unique consortium partners across 17 countries, STH has a broad European network built through large multi-centre clinical studies. Their connections span academic hospitals, universities, and medtech companies across Western and Central Europe.

What sets them apart

STH brings something most research institutions cannot: direct access to a large, diverse NHS patient population within a major teaching hospital setting. This makes them invaluable for clinical validation of digital health tools, imaging biomarkers, and patient outcome measurements where real-world healthcare data is essential. For consortium builders, partnering with STH means your innovation gets tested in one of the UK's busiest hospital systems — a credibility signal that matters for regulatory and clinical endorsement.

Highlights from their portfolio

• MOBILISE-D
  Large-scale validation of digital mobility biomarkers across five disease cohorts (COPD, Parkinson's, MS, ageing, hip fracture), directly targeting regulatory endorsement of digital endpoints.
• Hypo-RESOLVE
  Major diabetes data harmonization effort combining trial data from multiple sources to redefine hypoglycaemia classification — directly impacts clinical guidelines.
• EurValve
  Their largest funded project (EUR 454,047), developing personalised clinical decision support for heart valve disease using computational modelling.